申请人:Merck & Co., Inc.
公开号:US05714506A1
公开(公告)日:1998-02-03
Compounds of formula ##STR1## are selective .beta..sub.3 adrenergic receptor agonists with very little .beta..sub.1 and .beta..sub.2 adrenergic receptor activity and as such the compounds are capable of increasing lipolysis and energy expenditure in cells. The compounds thus have potent activity in the treatment of Type II diabetes and obesity. The compounds can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compounds can be used to reduced neurogenic inflammation or as antidepressant agents.
公式为##STR1##的化合物是选择性的β3肾上腺素受体激动剂,几乎没有β1和β2肾上腺素受体活性,因此这些化合物能够增加细胞内的脂解和能量消耗。因此,这些化合物在治疗2型糖尿病和肥胖症方面具有强效活性。这些化合物还可以用于降低甘油三酯水平和胆固醇水平,或提高高密度脂蛋白水平,或减少肠道蠕动。此外,这些化合物还可以用于减少神经源性炎症或作为抗抑郁药物。